Stanley B. Prusiner and the discovery of prions: implications for neurology

Notice: Blog posts are not subject to review by MedLink Neurology’s Editorial Board. MedLink acknowledges using artificial intelligence to assist in the creation of blog posts.

Stanley B. Prusiner MD is a neurologist and researcher whose work on prions has fundamentally altered the understanding of certain neurodegenerative diseases. He received the Nobel Prize in Physiology or Medicine in 1997 for his discovery of “prions”—infectious proteins that cause transmissible spongiform encephalopathies. His research has had a lasting impact on both fundamental neuroscience and clinical neurology, particularly in the context of protein misfolding diseases.

Clinical background and early research focus

Prusiner trained in neurology at the University of California, San Francisco (UCSF), where he later joined the faculty. His research into prion disease began after managing a patient with Creutzfeldt-Jakob disease in the early 1970s. At the time, Creutzfeldt-Jakob disease and related disorders were poorly understood, and no causative pathogen had been identified. These conditions were characterized by rapidly progressive dementia and invariably led to death.

In 1982, Prusiner published data supporting the hypothesis that the transmissible agent in these diseases was not a virus or bacterium, but a proteinaceous infectious particle, which he named the prion. His laboratory demonstrated that this agent was resistant to nucleic acid-degrading treatments but retained infectivity, suggesting that it lacked DNA or RNA.

Prion diseases and neurologic relevance

Prusiner’s work clarified the pathogenesis of transmissible spongiform encephalopathies, including:

• Scrapie in sheep
• Bovine spongiform encephalopathy in cattle
• Kuru, Creutzfeldt-Jakob disease, and fatal familial insomnia in humans

These diseases are now understood to result from the accumulation of an abnormal isoform of the prion protein, which converts the normal cellular form into the disease-associated form through a self-propagating mechanism.

Although rare, prion diseases remain clinically significant due to their rapid progression, lack of effective treatment, and implications for infection control in neurosurgical and transplant settings.

Broader impact on neurodegenerative disease research

Prusiner’s discovery also influenced the study of more common neurodegenerative diseases. Several conditions—including Alzheimer disease, Parkinson disease, and frontotemporal dementia—involve the misfolding and aggregation of proteins such as tau, beta-amyloid, alpha-synuclein, and TDP-43. Although these diseases are not infectious in the traditional sense, some protein aggregates appear to spread within the brain through prion-like mechanisms. This has led to the development of new research strategies and therapeutic approaches aimed at targeting protein misfolding, aggregation, and propagation.

Institutional and research leadership

Prusiner currently serves as director of the Institute for Neurodegenerative Diseases at UCSF. His work continues to focus on understanding the molecular mechanisms of prion propagation and identifying potential therapeutic targets. He has also contributed to policy discussions related to prion research and funding for neurologic diseases.

Conclusion

Stanley Prusiner’s identification of prions provided a mechanistic explanation for a group of previously unexplained neurodegenerative disorders. His work has had lasting relevance not only for rare prion diseases but also for the broader field of protein misfolding disorders. For clinicians, his research underscores the importance of recognizing rapid-onset dementias and maintaining awareness of prion-related pathology in differential diagnosis and infection control.

Related MedLink Neurology Podcast content:

• BrainWaves #39 What doesn't scare you about prions makes you stronger
• The Neurotransmitters: IM Board Prep #5: Dementia and Cognitive Decline

Related MedLink Neurology Blog content:

• From the jungles to Nobel to incarceration: Carleton Gajdusek and prion diseases
  

Are you interested in contributing a post or becoming a guest blogger for MedLink? Contact us at editorial@medlink.com.